+

WO2003033529A3 - Utilisation de tr4, d'activateurs de tr4, d'inhibiteurs de tr4 ou de molecules associees au tr4 pour traiter des leucemies - Google Patents

Utilisation de tr4, d'activateurs de tr4, d'inhibiteurs de tr4 ou de molecules associees au tr4 pour traiter des leucemies Download PDF

Info

Publication number
WO2003033529A3
WO2003033529A3 PCT/EP2002/011484 EP0211484W WO03033529A3 WO 2003033529 A3 WO2003033529 A3 WO 2003033529A3 EP 0211484 W EP0211484 W EP 0211484W WO 03033529 A3 WO03033529 A3 WO 03033529A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
activators
inhibitors
leukaemic
treating
Prior art date
Application number
PCT/EP2002/011484
Other languages
German (de)
English (en)
Other versions
WO2003033529A2 (fr
Inventor
Martin Zenke
Petr Bartunek
Jaime Madruga
Nicolas P Koritschoner
Original Assignee
Max Delbrueck Centrum
Martin Zenke
Petr Bartunek
Jaime Madruga
Nicolas P Koritschoner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum, Martin Zenke, Petr Bartunek, Jaime Madruga, Nicolas P Koritschoner filed Critical Max Delbrueck Centrum
Priority to AU2002362891A priority Critical patent/AU2002362891A1/en
Publication of WO2003033529A2 publication Critical patent/WO2003033529A2/fr
Publication of WO2003033529A3 publication Critical patent/WO2003033529A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne l'utilisation de TR4, d'activateurs de TR4, d'inhibiteurs de TR4 et/ou de molécules associées au TR4 en diagnostic, prévention, suivi, thérapeutique et/ou post-traitement de maladies tumorales et/ou de maladies du sang.
PCT/EP2002/011484 2001-10-12 2002-10-14 Utilisation de tr4, d'activateurs de tr4, d'inhibiteurs de tr4 ou de molecules associees au tr4 pour traiter des leucemies WO2003033529A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002362891A AU2002362891A1 (en) 2001-10-12 2002-10-14 Tr4, tr4 activators, tr4 inhibitors or tr4-associated molecules for treating leukaemic diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10150183A DE10150183A1 (de) 2001-10-12 2001-10-12 Mittel zur Behandlung von leukämischen Erkrankungen
DE10150183.8 2001-10-12

Publications (2)

Publication Number Publication Date
WO2003033529A2 WO2003033529A2 (fr) 2003-04-24
WO2003033529A3 true WO2003033529A3 (fr) 2003-11-20

Family

ID=7702165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/011484 WO2003033529A2 (fr) 2001-10-12 2002-10-14 Utilisation de tr4, d'activateurs de tr4, d'inhibiteurs de tr4 ou de molecules associees au tr4 pour traiter des leucemies

Country Status (3)

Country Link
AU (1) AU2002362891A1 (fr)
DE (1) DE10150183A1 (fr)
WO (1) WO2003033529A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2651555A1 (fr) * 2006-05-09 2007-11-22 University Of Rochester Procedes et compositions lies a tr4
US20210162007A1 (en) * 2018-04-09 2021-06-03 President And Fellows Of Harvard College Modulating nuclear receptors and methods of using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135493A (ja) * 1997-07-17 1999-02-09 Sumitomo Pharmaceut Co Ltd 新規な抗エストロジェン遺伝子治療剤
WO2001016368A1 (fr) * 1999-09-01 2001-03-08 Bristol-Myers Squibb Company Systemes de transcription in vitro et ses utilisations
WO2001035101A2 (fr) * 1999-11-12 2001-05-17 University Of Rochester Suppression mutuelle entre des recepteurs d'hormones sexuelles et d'autres recepteurs nucleaires

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135493A (ja) * 1997-07-17 1999-02-09 Sumitomo Pharmaceut Co Ltd 新規な抗エストロジェン遺伝子治療剤
WO2001016368A1 (fr) * 1999-09-01 2001-03-08 Bristol-Myers Squibb Company Systemes de transcription in vitro et ses utilisations
WO2001035101A2 (fr) * 1999-11-12 2001-05-17 University Of Rochester Suppression mutuelle entre des recepteurs d'hormones sexuelles et d'autres recepteurs nucleaires

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARTUNEK PETR ET AL: "Retinoid X receptor and c-erbA/thyroid hormone receptor regulate erythroid cell growth and differentiation.", MOLECULAR ENDOCRINOLOGY, vol. 12, no. 9, 1998, pages 1269 - 1279, XP002235922, ISSN: 0888-8809 *
DATABASE WPI Section Ch Week 200125, Derwent World Patents Index; Class B04, AN 2001-244411, XP002235924 *
KORITSCHONER NICOLAS P ET AL: "The nuclear orphan receptor TR4 promotes proliferation of myeloid progenitor cells.", CELL GROWTH & DIFFERENTIATION, vol. 12, no. 11, November 2001 (2001-11-01), pages 563 - 572, XP002235923, ISSN: 1044-9523 *
NASON-BURCHENAL KATHRYN ET AL: "RXRa overexpression in NB4 promyelocytic leukemia cells is growth inhibitory and renders the transfectants more sensitive to retinoid induced differentiation.", ANTICANCER RESEARCH, vol. 17, no. 5C, 1997, Seventh International Conference on Differentiation Therapy;Versailles, France; October 5-8, 1997, pages 3951, XP001146567, ISSN: 0250-7005 *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 05 31 May 1999 (1999-05-31) *

Also Published As

Publication number Publication date
WO2003033529A2 (fr) 2003-04-24
AU2002362891A1 (en) 2003-04-28
DE10150183A1 (de) 2003-04-24

Similar Documents

Publication Publication Date Title
WO2003073999A3 (fr) Composes de modulation de pin1 et procedes d'utilisation correspondant
WO2003074550A3 (fr) Composes de modulation de pin1 et procedes d'utilisation correspondant
WO2002074337A8 (fr) Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
EA200801717A1 (ru) Композиция местного применения по уходу за кожей, продукт на ее основе и способ лечения
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
EP1455778A4 (fr) Procedes de traitement de malaises neurovasculaires peripheriques
MXPA03001960A (es) Un metodo para tratar alergias.
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
TNSN04015A1 (en) Combination therapy for the treatment of cancer
WO2005007123A3 (fr) Composes modulateurs de pin-1 et methodes d'utilisation associees
MXPA02002117A (es) Uso de productos leguminosos para el tratamiento de agresiones externas.
NO20062229L (no) Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er)
PL373528A1 (en) Medicine for preventing and treating bromidrosis
ATE337005T1 (de) Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
WO2003061704A3 (fr) Traitement combine d'infections bacteriennes
WO2003033529A3 (fr) Utilisation de tr4, d'activateurs de tr4, d'inhibiteurs de tr4 ou de molecules associees au tr4 pour traiter des leucemies
WO2003094967A3 (fr) Nouvelle combinaison destinee au traitement des troubles des voies aeriennes
WO2003080800A3 (fr) Prevention et traitement de maladies au moyen d'angiogenese et/ou d'antigenes tumoraux
WO2003079748A3 (fr) Renforcement de therapies cancereuses par inhibition de znf217
WO2002055096A3 (fr) Utilisation topique d'huiles essentielles
UA85187C2 (en) 2-aminobenzoyl derivatives
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载